Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
Related Questions
When can we expect preliminary data or results from the NIGHTINGALE trial, and how might that influence the share price?
What is the potential market size for the Percepta Nasal Swab lung cancer test compared with existing diagnostics, and how will Veracyte capture market share?
How will the completion of enrollment in the NIGHTINGALE trial affect Veracyte's short‑term cash flow and valuation?